Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: id:"swepub:oai:prod.swepub.kib.ki.se:150328596" > Ras-Related Protein...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Kosibaty, Z (author)

Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer

Article/chapterEnglish2022

Publisher, publication year, extent ...

2022-07-14
MDPI AG,2022

Numbers

LIBRIS-ID:oai:prod.swepub.kib.ki.se:150328596
http://kipublications.ki.se/Default.aspx?queryparsed=id:150328596URI
https://doi.org/10.3390/cancers14143430DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

Treatment with the tyrosine kinase inhibitor (TKI) osimertinib is the standard of care for non-small cell lung cancer (NSCLC) patients with activating mutations in the epidermal growth factor receptor (EGFR). Osimertinib is also used in T790M-positive NSCLC that may occur de novo or be acquired following first-line treatment with other EGFR TKIs (i.e., gefitinib, erlotinib, afatinib, or dacomitinib). However, patients treated with osimertinib have a high risk of developing resistance to the treatment. A substantial fraction of the mechanisms for resistance is unknown and may involve RNA and/or protein alterations. In this study, we investigated the full transcriptome of parental and osimertinib-resistant cell lines, revealing 131 differentially expressed genes. Knockdown screening of the genes upregulated in resistant cell lines uncovered eight genes to partly confer resistance to osimertinib. Among them, we detected the expression of Ras-related protein Rab-32 (RAB32) and thrombospondin 1 (THBS1) in plasmas sampled at baseline and at disease progression from EGFR-positive NSCLC patients treated with osimertinib. Both genes were upregulated in progression samples. Moreover, we found that knockdown of RAB32 and THBS1 reduced the expression of phosphorylated focal adhesion kinase (FAK). Combination of osimertinib with a FAK inhibitor resulted in synergistic toxicity in osimertinib-resistant cells, suggesting a potential therapeutic drug combination for overcoming resistance to osimertinib in NSCLC patients.

Added entries (persons, corporate bodies, meetings, titles ...)

Brustugun, OT (author)
Eide, IJZ (author)
Tsakonas, GKarolinska Institutet (author)
Grundberg, OKarolinska Institutet (author)
De Petris, LKarolinska Institutet (author)
McGowan, M (author)
Hydbring, PKarolinska Institutet (author)
Ekman, SKarolinska Institutet (author)
Karolinska Institutet (creator_code:org_t)

Related titles

In:Cancers: MDPI AG14:142072-6694

Internet link

Find in a library

Cancers (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Kosibaty, Z; Brustugun, OT; Eide, IJZ; Tsakonas, G; Grundberg, O; De Petris, L; show more...; McGowan, M; Hydbring, P; Ekman, S; show less...

Articles in the publication: Cancers

By the university: Karolinska Institutet

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se